BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint

BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary efficacy endpoint, showcasing a reduction in blood phenylalanine (Phe) levels in adolescents with phenylketonuria (PKU) against only diet.